Molnupiravir provides little benefit in vaccinated adults with COVID-19.

Overview of: Butler CC, Hobbs FDR, Gbinigie OA, et al Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 2023;401:281-93. © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Citation

Molnupiravir provides little benefit in vaccinated adults with COVID-19. Drug and therapeutics bulletin. 2023 Jun;61(6):84

Mesh Tags

Substances

PMID: 37068918

search → result